Bimekizumab Led to Sustained Improvements in Health-Related Quality of Life and Work Productivity in Patients With Axial Spondyloarthritis: 3-Year Results From Two Phase 3 Studies
Author(s)
Elena Nikiphorou, PhD1, Martin Rudwaleit, PhD2, Mark Hwang, PhD3, Pedro M Machado, PhD4, Atul Deodhar, MD5, Maureen Dubreuil, MSc, MD6, Sarah Kavanagh, PhD7, Vanessa Taieb, MSc8, Christine De La Loge, MSc9, Michael Frank Mørup, MSc10, Annelies Boonen, PhD11.
1Centre for Rheumatic Diseases, King’s College London & Rheumatology Department, King’s College Hospital, London, United Kingdom, 2Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, 3Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, USA, 4Department of Rheumatology, University College London Hospitals NHS Foundation Trust; Northwick Park Hospital, London North West University Healthcare NHS Trust; Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 5Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA, 6Section of Rheumatology, Boston University School of Medicine, Boston, MA, USA, 7UCB, Morrisville, NC, USA, 8UCB, Colombes, France, 9UCB, Brussels, Belgium, 10UCB, Copenhagen, Denmark, 11Department of Rheumatology, Maastricht University Medical Center; Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands.
1Centre for Rheumatic Diseases, King’s College London & Rheumatology Department, King’s College Hospital, London, United Kingdom, 2Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, 3Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, USA, 4Department of Rheumatology, University College London Hospitals NHS Foundation Trust; Northwick Park Hospital, London North West University Healthcare NHS Trust; Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 5Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA, 6Section of Rheumatology, Boston University School of Medicine, Boston, MA, USA, 7UCB, Morrisville, NC, USA, 8UCB, Colombes, France, 9UCB, Brussels, Belgium, 10UCB, Copenhagen, Denmark, 11Department of Rheumatology, Maastricht University Medical Center; Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands.
OBJECTIVES: To report long-term impact of bimekizumab (BKZ) treatment on health-related quality of life (HRQoL) and work productivity to 3 years in patients with axial spondyloarthritis (axSpA).
METHODS: All BE MOBILE 1 (NCT03928704; non-radiographic [nr-]axSpA) and 2 (NCT03928743; radiographic [r-]axSpA) patients received subcutaneous BKZ 160mg every 4 weeks from Week (Wk)16. At Wk52, eligible patients could enter the open-label extension, BE MOVING (NCT04436640; ongoing). To assess HRQoL, we report change from baseline (CfB) in Ankylosing Spondylitis Quality of Life (ASQoL; multiple imputation [MI]), EuroQoL visual analogue scale (EQ-VAS; observed case [OC]) and Short Form-36 (SF-36) domain scores (MI), and the proportion of patients achieving a ≥4-point reduction (improvement) in ASQoL (non-responder imputation). For employed patients, CfB and the proportion achieving a ≥15% decrease from baseline in Work Productivity and Activity Impairment Questionnaire (WPAI:axSpA) overall work impairment (OC) are reported.
RESULTS: 86.6% (nr-axSpA; 220/254) and 89.8% (r-axSpA; 298/332) of randomised patients completed Wk52; 68.9% (175/254) and 75.3% (250/332) completed Wk164. ASQoL improvements were sustained from Wk52 (mean CfB nr-axSpA: −5.6; r-axSpA: −5.6) to Wk164 (nr-axSpA: -5.6; r-axSpA: −5.6). At Wk164, 51.8% (nr-axSpA) and 58.5% (r-axSpA) had a ≥4-point ASQoL reduction from baseline. EQ-VAS improvements were sustained from Wk52 (mean CfB nr-axSpA: +22.1; r-axSpA: +18.9) to Wk164 (nr-axSpA: +21.3; r-axSpA: +20.2). Improvements across all SF-36 domains were seen at Wk164 (least improvement, mean CfB: Role Emotional [nr-axSpA: +2.0; r-axSpA: +3.0]; most improvement: Bodily Pain [nr-axSpA: +12.5; r-axSpA: +13.4]). WPAI:axSpA overall work impairment improvements in employed patients were sustained from Wk52 (mean CfB nr-axSpA[n=127]: −28.1; r-axSpA[n=183]: −25.8) to Wk164 (nr-axSpA[n=105]: −29.3; r-axSpA[n=144]: −28.8). At Wk164, 74.0% (nr-axSpA), and 81.1% (r-axSpA) of employed patients achieved a ≥15% decrease from baseline in overall work impairment.
CONCLUSIONS: BKZ resulted in sustained improvements in patient-reported measures of HRQoL and work productivity to 3 years, across the full disease spectrum of axSpA.
METHODS: All BE MOBILE 1 (NCT03928704; non-radiographic [nr-]axSpA) and 2 (NCT03928743; radiographic [r-]axSpA) patients received subcutaneous BKZ 160mg every 4 weeks from Week (Wk)16. At Wk52, eligible patients could enter the open-label extension, BE MOVING (NCT04436640; ongoing). To assess HRQoL, we report change from baseline (CfB) in Ankylosing Spondylitis Quality of Life (ASQoL; multiple imputation [MI]), EuroQoL visual analogue scale (EQ-VAS; observed case [OC]) and Short Form-36 (SF-36) domain scores (MI), and the proportion of patients achieving a ≥4-point reduction (improvement) in ASQoL (non-responder imputation). For employed patients, CfB and the proportion achieving a ≥15% decrease from baseline in Work Productivity and Activity Impairment Questionnaire (WPAI:axSpA) overall work impairment (OC) are reported.
RESULTS: 86.6% (nr-axSpA; 220/254) and 89.8% (r-axSpA; 298/332) of randomised patients completed Wk52; 68.9% (175/254) and 75.3% (250/332) completed Wk164. ASQoL improvements were sustained from Wk52 (mean CfB nr-axSpA: −5.6; r-axSpA: −5.6) to Wk164 (nr-axSpA: -5.6; r-axSpA: −5.6). At Wk164, 51.8% (nr-axSpA) and 58.5% (r-axSpA) had a ≥4-point ASQoL reduction from baseline. EQ-VAS improvements were sustained from Wk52 (mean CfB nr-axSpA: +22.1; r-axSpA: +18.9) to Wk164 (nr-axSpA: +21.3; r-axSpA: +20.2). Improvements across all SF-36 domains were seen at Wk164 (least improvement, mean CfB: Role Emotional [nr-axSpA: +2.0; r-axSpA: +3.0]; most improvement: Bodily Pain [nr-axSpA: +12.5; r-axSpA: +13.4]). WPAI:axSpA overall work impairment improvements in employed patients were sustained from Wk52 (mean CfB nr-axSpA[n=127]: −28.1; r-axSpA[n=183]: −25.8) to Wk164 (nr-axSpA[n=105]: −29.3; r-axSpA[n=144]: −28.8). At Wk164, 74.0% (nr-axSpA), and 81.1% (r-axSpA) of employed patients achieved a ≥15% decrease from baseline in overall work impairment.
CONCLUSIONS: BKZ resulted in sustained improvements in patient-reported measures of HRQoL and work productivity to 3 years, across the full disease spectrum of axSpA.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR33
Topic
Patient-Centered Research, Study Approaches
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Biologics & Biosimilars, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)